ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Addressing these issues, second-generation (2G) TKIs have also been approved for the frontline treatment of CML, since they achieve both faster hematologic and cytogenetic responses and deeper reductions in BCR::ABL1/ABL1 transcript levels [7].